Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2016 2
2017 1
2018 1
2020 3
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020.
Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, Bernard PV, Biala JS, Blanc FX, Bogorodskaya EM, Borisov S, Buonsenso D, Calnan M, Castellotti PF, Centis R, Chakaya JM, Cho JG, Codecasa LR, D'Ambrosio L, Denholm J, Enwerem M, Ferrarese M, Galvão T, García-Clemente M, García-García JM, Gualano G, Gullón-Blanco JA, Inwentarz S, Ippolito G, Kunst H, Maryandyshev A, Melazzini M, de Queiroz Mello FC, Muñoz-Torrico M, Njungfiyini PB, Palmero DJ, Palmieri F, Piccioni P, Piubello A, Rendon A, Sabriá J, Saporiti M, Scognamiglio P, Sharma S, Silva DR, Souleymane MB, Spanevello A, Tabernero E, Tadolini M, Tchangou ME, Thornton ABY, Tiberi S, Udwadia ZF, Sotgiu G, Ong CWM, Goletti D. Migliori GB, et al. Among authors: enwerem m. Emerg Infect Dis. 2020 Nov;26(11):2709-2712. doi: 10.3201/eid2611.203163. Epub 2020 Sep 11. Emerg Infect Dis. 2020. PMID: 32917293 Free PMC article.
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, Ferreira H, Hughes J, Joseph L, Kock Y, Letsaolo V, Maartens G, Meintjes G, Ngcamu D, Okozi N, Padanilam X, Reuter A, Romero R, Schaaf S, Te Riele J, Variava E, van der Meulen M, Ismail F, Ndjeka N. Ismail NA, et al. Among authors: enwerem m. Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12. Lancet Infect Dis. 2022. PMID: 34780706
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, Padanilam X, Reuter A, Romero R, Ismail F, Enwerem M, Ferreira H, Conradie F, Naidoo K, Menzies D. Ndjeka N, et al. Among authors: enwerem m. Lancet Infect Dis. 2022 Jul;22(7):1042-1051. doi: 10.1016/S1473-3099(21)00811-2. Epub 2022 May 2. Lancet Infect Dis. 2022. PMID: 35512718 Free PMC article.
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
Ndjeka N, Conradie F, Meintjes G, Reuter A, Hughes J, Padanilam X, Ismail N, Kock Y, Master I, Romero R, Te Riele J, Enwerem M, Ferreira H, Maartens G. Ndjeka N, et al. Among authors: enwerem m. Eur Respir J. 2020 Jul 23;56(1):2001369. doi: 10.1183/13993003.01369-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32471936 Free PMC article.
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, Conradie F. Ndjeka N, et al. Among authors: enwerem m. Eur Respir J. 2018 Dec 20;52(6):1801528. doi: 10.1183/13993003.01528-2018. Print 2018 Dec. Eur Respir J. 2018. PMID: 30361246 Free article.
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB. Borisov SE, et al. Among authors: enwerem m. Eur Respir J. 2017 May 21;49(5):1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May. Eur Respir J. 2017. PMID: 28529205 Free article.
Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder.
Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku OS, Bamgboye EA, Nasipuri RN, Kunle OO, Okogun JI, Enwerem MN, Audam JG, Gamaniel KS, Obodozie OO, Samuel B, Fojule G, Ogunyale O. Wambebe C, et al. Among authors: enwerem mn. Phytomedicine. 2001 Jul;8(4):252-61. doi: 10.1078/0944-7113-00040. Phytomedicine. 2001. PMID: 11515714 Clinical Trial.